Summit updates survival data for Akeso-partnered lung cancer drug
Seeking Alpha ·
Summit Therapeutics ( SMMT ) lost ~1% in the premarket on Wednesday after the company shared the latest data on overall survival from a late-stage trial for ivonescimab, a lung cancer therapy it is developing with Chinese biotech Akeso ( AKESF ).
AI 시장 분석
Summit Therapeutics released the final overall survival data from the late-stage clinical trial of ivonescimab, a lung cancer treatment being co-developed with Chinese biotech Akeso. Following the news, the stock fell about 1% in the pre-market, showing a somewhat disappointing market reaction. Investors need to closely monitor the specific survival data trends from large-scale clinical results.
하락 영향
- Biotech — The stock fell 1% in the pre-market due to the dissipation of pre-priced expectations and uncertainties following the release of late-stage clinical survival data for ivonescimab.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 52% · Bearish (Short) 48%
469 participants
Related News
- VAT Group AG GAAP EPS of CHF 3.30, revenue of CHF 511.9M
- Ondas Holdings secures $70M in new defense orders
- Norwood Financial GAAP EPS of $0.86 in-line, revenue of $29.3M beats by $1.2M
- J&J wins FDA nod for Ottava surgical robot
- HSBC upgrades Goldman Sachs, raises price target on Morgan Stanley
- SSAB AB (publ) GAAP EPS of SEK 2.09, revenue of SEK 27.49B
